TD Cowen cuts ICON stock price target to $254, maintains Buy rating
TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.
Icon Energy sets price for public offering of units
Energy Corp. (NASDAQ:ICON), a global dry bulk shipping service provider, has announced the pricing of its public offering of over 9 million units at $1.31 each. According to InvestingPro data, this ...
ICON Backs Annual Guidance, Initiates 2025 Outlook; Pre-Market Stock Down
ICON Plc (ICLR), healthcare intelligence and clinical research company, on Tuesday reaffirmed its annual guidance. In addition, the ...
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts ...
Icon’s Strategic Positioning and Undervalued Potential: A Buy Recommendation
Analyst Michael Cherny from Leerink Partners reiterated a Buy rating on Icon (ICLR – Research Report) and decreased the price target to $245.00 ...
Morningstar12d
ICON Issues Financial Guidance for Full Year 2025
ICON plc, (NASDAQ: ICLR), a world-leading clinical ... In quarter four 2024, the company repurchased a total of $400 million worth of stock at an average price of $217. For the full year 2024 ...